Arcellx inc ACLX.US 總覽分析
ACLX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位
ACLX 近期報酬表現
3.39%
Arcellx inc
4.57%
同產業平均
3.26%
S&P500
與 ACLX 同產業的標的表現
- APGE Apogee therapeutics inc價值 -趨勢 3 分波段 5 分籌碼 3 分股利 1 分查看更多
ACLX 公司資訊
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).